Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee.

Autor:	Mino-Kenudson M; Department of Pathology, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts., Schalper K; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut., Cooper W; Royal Prince Alfred Hospital, NSW Health Pathology and University of Sydney, Camperdown, Australia., Dacic S; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut., Hirsch FR; Center for Thoracic Oncology, The Tisch Cancer Institute, New York, New York; Icahn School of Medicine, Mount Sinai Health System, New York, New York., Jain D; All India Institute of Medical Sciences, New Delhi, India., Lopez-Rios F; Department of Pathology, 'Doce de Octubre' University Hospital, Madrid, Spain., Tsao MS; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Yatabe Y; National Cancer Center Hospital, Tokyo, Japan., Beasley MB; Icahn School of Medicine, Mount Sinai Health System, New York, New York., Yu H; Center for Thoracic Oncology, The Tisch Cancer Institute, New York, New York; Icahn School of Medicine, Mount Sinai Health System, New York, New York., Sholl LM; Department of Pathology, Brigham and Women's Hospital & Harvard Medical School, Boston, Massachusetts., Brambilla E; Université Grenoble Alpes, Grenoble, France., Chou TY; Taipei Veterans General Hospital, Taipei, Taiwan., Connolly C; International Association for the Study of Lung Cancer, Denver, Colorado., Wistuba I; The University of Texas MD Anderson Cancer Center, Houston, Texas., Kerr KM; Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom., Lantuejoul S; Université Grenoble Alpes, Grenoble, France; Centre Léon Bérard Unicancer, Lyon, France. Electronic address: Sylvie.LANTUEJOUL@lyon.unicancer.fr.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Dec; Vol. 17 (12), pp. 1335-1354. Date of Electronic Publication: 2022 Sep 29.
DOI:	10.1016/j.jtho.2022.09.109
Abstrakt:	Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of treatment for most lung cancers with advanced or metastatic disease. In addition, they have increasingly been used for early stage tumors in neoadjuvant and adjuvant settings. Unfortunately, however, only a subset of patients experiences meaningful response to ICIs. Although programmed death-ligand 1 (PD-L1) protein expression by immunohistochemistry (IHC) has played a role as the principal predictive biomarker for immunotherapy, its performance may not be optimal, and it suffers multiple practical issues with different companion diagnostic assays approved. Similarly, tumor mutational burden (TMB) has multiple technical issues as a predictive biomarker for ICIs. Now, ongoing research on tumor- and host immune-specific factors has identified immunotherapy biomarkers that may provide better response and prognosis prediction, in particular in a multimodal approach. This review by the International Association for the Study of Lung Cancer Pathology Committee provides an overview of various immunotherapy biomarkers, including updated data on PD-L1 IHC and TMB, and assessments of neoantigens, genetic and epigenetic signatures, immune microenvironment by IHC and transcriptomics, and microbiome and pathologic response to neoadjuvant immunotherapies. The aim of this review is to underline the efficacy of new individual or combined predictive biomarkers beyond PD-L1 IHC and TMB. (Copyright © 2022 International Association for the Study of Lung Cancer. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu